Lantheus Holdings, Inc. $LNTH Holdings Lowered by TD Asset Management Inc

TD Asset Management Inc trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 711,894 shares of the medical equipment provider’s stock after selling 79,056 shares during the period. TD Asset Management Inc’s holdings in Lantheus were worth $47,377,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of LNTH. M&T Bank Corp purchased a new stake in shares of Lantheus in the fourth quarter valued at $370,950,000. Norges Bank purchased a new stake in shares of Lantheus in the fourth quarter valued at $76,197,000. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Lantheus in the third quarter valued at $11,443,000. Reinhart Partners LLC. lifted its holdings in shares of Lantheus by 15.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Lantheus by 73.4% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock valued at $23,001,000 after purchasing an additional 189,814 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $100.98 on Friday. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00. The business has a fifty day simple moving average of $88.01 and a 200 day simple moving average of $74.96. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the company earned $1.53 earnings per share. Lantheus’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Citizens Jmp increased their target price on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Jefferies Financial Group restated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Finally, Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.